Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection

American Journal of Tropical Medicine and Hygiene

Volumn 77, Issue 6, 2007, Pages 1135-1138

  Dimaano, Efren M ^b   Saito, Mariko ^c   Honda, Shoko ^c   Miranda, Edna A ^b   Alonzo, Maria T G ^d   Valerio, Myra D ^d   Mapua, Cynthia A ^d   Inoue, Shingo ^c   Kumaori, Atsushi ^e   Matias, Ronald ^d   Natividad, Filipinas F ^d   Oishi, Kazunori ^a  

^a OSAKA UNIVERSITY   (Japan)

^b San Lazaro Hospital   (Philippines)

^c NAGASAKI UNIVERSITY   (Japan)

^d ST LUKE S MEDICAL CENTER   (Philippines)

^e CHIBA INSTITUTE OF SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; GAMMAMUNE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DEMOGRAPHY; DENGUE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; HUMAN; MACROPHAGE; MALE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; BLOOD; CHILD; DENGUE VIRUS; DRUG EFFECT; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGY; PHILIPPINES; THROMBOCYTE; TIME; TREATMENT OUTCOME; VIROLOGY;

DENGUE VIRUS;

ADOLESCENT; ADULT; BLOOD PLATELETS; CHILD; DENGUE; DENGUE VIRUS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; PHILIPPINES; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 39049118442     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2007.77.1135     Document Type: Article

References (20)

1. Halstead SB, 1988. Pathogenesis of dengue: challenges of molecular biology. Science 239: 476-481.
2. La Russa VF, Innis BL, 1995. Mechanism of dengue virus-induced bone marrow suppression. Baillieres Clin Hematol 8: 249-270.
3. Oishi K, Saito M, Mapua CA, Natividad FF, 2007. Dengue illness: clinical features and pathogenesis. J Infect Chemother 13: 125-133.
4. Gubler DJ, 2002. Epidemic dengue/ dengue hemorrhagic fever as a public health, social and economic problems in the 21st century. Trends Microbiol 10: 100-103.
5. McMillan R, 1981. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 304: 1135-1147.
6. Cines DB, Blanchette VS, 2002. Immune thrombocytopenic purpura. N Engl J Med 346: 995-1008.
7. Crow AR, Song S, Siragam V, Lazarus AH, 2006. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia. Pediatr Blood Cancer 47: 710-713.
8. Oishi K, Inoue S, Cinco MT, Dimaano EM, Alera MT, Alfon JA, Abanes F, Cruz DJ, Matias RR, Matsuura H, Hasebe F, Tanimura S, Kumatori A, Morita K, Natividad FF, Nagatake T, 2003. Correlation between increased platelet-associated IgG and thrombocytopenia in secondary dengue virus infections. J Med Virol 71: 259-264.
9. Saito M, Oishi K, Inoue S, Dimaano EM, Alera MTP, Robles MP, Estrella JR, Kumatori A, Moji K, Alonzo BMT, Buerano CC, Matias RR, Morita K, Natividad FF, Nagatake T, 2004. Association of increased platelet-associated immunoglobulins with thrombocytopenia and the severity of disease in secondary dengue virus infections. Clin Exp Immunol 138: 299-303.
10. Ascher DP, Laws HF, Hayes CG, 1989. The use of intravenous gammaglobulin in dengue fever, a case report. Southeast Asian J Trop Med Pub Hlth 20: 549-554.
11. World Health Organization, 1997. Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention and Control. Second edition. Geneva: World Health Organization.
12. Berlioz-Arthaud A, Martel M, Durand AM, Ogawa T, 2005. Evaluation of a new anti-dengue virus IgM particle agglutination kit in the context of the Pacific islands. World Health Organ Dengue Bull 29: 70-78.
13. Bundo K, Igarashi A, 1985. Antibody-capture ELISA for detection of immunoglobulin M antibodies in sera from Japanese encephalitis and dengue hemorrhagic fever patients. J Virol Methods 11: 15-22.
14. Morita K, Tanaka M, Igarashi A, 1991. Rapid identification of dengue virus serotypes by using polymerase chain reaction. J Clin Microbiol 29: 2107-2110.
15. Clarke DH, Casals J, 1958. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. Am J Trop Med Hyg 7: 561-573.
16. Kurlander RJ, Roose WF, 1986. Efficacy of a 2-day schedule for administering intravenous immunoglobulin (IVIg) in treating adults with ITP. Blood 291: 484.
17. Bierling P, Godeau B, 2005. Intravenous immunoglobulin for autoimmune thrombocytopenic purpura. Human Immunol 66: 387-394.
18. Avirutnan P, Punyanadee N, Noisaran S, Komoltri C, Thiemmeca S, Auethavornanan K, Jairungsri A, Kanlaya R, Tangtawornchailul N, Puttikhunt C, Pattnakisakul S, Yenchitsomnus P, Mongkolsapaya J, Kasinrerk W, Sittisombut N, Husmann M, Blettner M, Vasanawathana S, Bhakdi S, Mlasit P, 2006. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 193: 1078-1088.
19. de Castro RA, de Castro JA, Barez M, Frias M, Dixit J, Genereux M, 2007. Thrombocytopenia associated with dengue hemorrhagic fever responds to intravenous administration of anti-D (Rh(0)-D) immune globulin. Am J Trop Med Hyg 76: 737-742.
20. Scaradavou A, Woo B, Woloski BM, Cunningham-Rundles S, Ettinger LJ, Aledort LM, Bussel JM, 1997. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 89: 2689-2700.